Clalit Health Services, DayTwo Announce Partnership

Clalit Health Services and DayTwo are partnering to bring to market a glycemic-control product for people with Type 2 diabetes. The glycemic-control offering is based on the genetic sequencing of gut microbiome and additional personal and clinical parameters. The glycemic-control product will be offered to Clalit members at the beginning of 2019.

The technology was developed following a study by Prof. Eran Segal, and Prof. Eran Elinav of the Weizmann Institute of Science, who discovered that the same foods cause different blood sugar reactions in different people (Cell, Nov 2015). This discovery led to the development of a machine learning algorithm that predicts each person's individual blood sugar response to a wide variety of foods and offers nutritional recommendations tailored to each person's personal profile.

The DayTwo glycemic-control offering will be integrated into Clalit's nutrition and dietetic services. Clalit's members will be able to order a test kit, provide microbiome samples for genetic sequencing, and answer a health questionnaire. After sequencing, Clalit members will receive a personalized nutrition plan, using a unique application that will help maintain balanced glycemic levels and will also receive online consultations with Clalit's registered dietitians for meal-planning assistance and onboarding.

"Science and technology have the potential to unlock our body's secrets to improve our health. We congratulate Clalit for choosing to lead and embrace science and technology where they can be applied to personalized medicine today," Lihi Segal, CEO and Co-Founder of DayTwo said. "Our partnership is another step in Clalit's leadership to provide state-of-the-art healthcare and well-being for their members."

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.